Syndax reports high remission rates in frontline revumenib combination trials ahead of ASH 2026
SNDX•SNDX•SNDX•SNDX•Syndax Pharmaceuticals will present data on revumenib and axatilimab at the American Society of Hematology meeting, December 12-15, 2026. Accepted abstracts include 14 on revumenib, seven with oral presentations, and five on axatilimab.
Syndax Pharmaceuticals will report data on revumenib and axatilimab at the American Society of Hematology meeting in New Orleans, December 12-15, 2026. The accepted abstracts include 14 for revumenib, seven featuring oral presentations, and five for axatilimab.
Updated frontline revumenib combination studies showed encouraging remission, measurable residual disease clearance and survival outcomes in newly diagnosed acute myeloid leukemia. Long-term axatilimab findings suggest potential for prolonged clinical benefit in relapsed or refractory chronic graft-versus-host disease.
